(Q56982741)

1

0 references

Johannes F. Mann

2

0 references

Günter Stein

3

0 references

Ute Jansa

4

0 references

Pascale Oddou-Stock

5

0 references

Dirk Spormann

6

0 references

Roger Heath

7

0 references

Karl-Günther Klingl

8

0 references

Frederic Bodin

9

0 references

Friedrich C. Luft

Current Therapeutic Research

10

0 references

publication date

March 1999

0 references

published in

0 references

volume

60

0 references

issue

3

0 references

page(s)

170-183

0 references

cites work

Membranous glomerulopathy in a patient on captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Recurrent angiotensin-converting enzyme inhibitor--associated angioedema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Angiotensin receptor antagonists: focus on losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Pharmacology of angiotensin II receptors in the kidney.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. Subcommittee of WHO/ISH Mild Hypertension Liaison committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Renal effects of angiotensin II receptor blockade in normotensive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Angiotensin-converting enzyme (ACE) inhibitors have been reported to induce or worsen anemia in patients on hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6

Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-393X%2800%2988527-6